SEARCH

SEARCH BY CITATION

References

  • 1
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745750.
  • 2
    Poynard T, Yuen M-F, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 20952100.
  • 3
    National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002–June 10–12, 2002. HEPATOLOGY 2002; 36(Suppl): S3S20.
  • 4
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 5
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
  • 6
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.
  • 7
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 14931499.
  • 8
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 14851492.
  • 9
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 14261432.
  • 10
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 11
    Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004; 40: 12601265.
  • 12
    von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alfa-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129: 522527.
  • 13
    Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 26092617.
  • 14
    US Food and Drug Administration. An update on the approval of BLA 103949/5002, PEG-Intron™ (peginterferon alfa-2b) powder for injection, indicated for use alone or in combination with Rebetol (ribavirin, USP) for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alfa and are at least 18 years of age. US Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/docket/ac/01/briefing/3819b1.htm. Accessed July 10, 2006.
  • 15
    US Food and Drug Administration. Briefing materials updating information the safety and efficacy of PEGASYS® in combination with COPEGUS™ for the treatment of adult patients with chronic hepatitis C infection, and to discuss questions about dosing that may result in postmarketing studies, FDA. US Food and Drug Administration Web site. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/02/briefing/3909b1.htm. Accessed August 1, 2007.
  • 16
    European Medicines Agency. Pegasys European Public Assessment Report. Scientific Discussion. European Medicines Agency Web site. Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/pegasys/pegasys.htm. Accessed August 1, 2007.